{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:52:10Z","timestamp":1792291930899,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20199076"],"award-info":[{"award-number":["3502Z20199076"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014125","name":"Fujian Provincial Health Commission","doi-asserted-by":"publisher","award":["2019-2-53"],"award-info":[{"award-number":["2019-2-53"]}],"id":[{"id":"10.13039\/501100014125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pediatr-neonatol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics & Neonatology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.pedneo.2021.11.010","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:14:01Z","timestamp":1643739241000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records"],"prefix":"10.1016","volume":"63","author":[{"given":"Quanyao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pedneo.2021.11.010_bib1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pedneo.2021.11.010_bib2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pedneo.2021.11.010_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12879-015-0813-3","article-title":"Prevalence of early-onset neonatal infection among newborns of mothers with bacterial infection or colonization: a systematic review and meta-analysis","volume":"15","author":"Chan","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/jac\/dkv451","article-title":"Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates","volume":"71","author":"Ramos-Mart\u00edn","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pedneo.2021.11.010_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/jcn.JCN_105_20","article-title":"The predictive factors for poor outcomes in preterm infants with coagulase-negative staphylococci infection","volume":"10","author":"Al-Matary","year":"2021","journal-title":"J Clin Neonatol"},{"issue":"Suppl. 2","key":"10.1016\/j.pedneo.2021.11.010_bib6","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib7","first-page":"43","article-title":"Antimicrobial resistance profile of clinical isolates in pediatric hospitals in China: report from the ISPED Surveillance Program in 2019","volume":"16","author":"Fu","year":"2021","journal-title":"Chin J Evid Based Pediatr"},{"key":"10.1016\/j.pedneo.2021.11.010_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib9","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/jpc.14683","article-title":"Vancomycin therapeutic drug monitoring in paediatrics","volume":"56","author":"Patel","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.pedneo.2021.11.010_bib11","doi-asserted-by":"crossref","first-page":"106150","DOI":"10.1016\/j.ijantimicag.2020.106150","volume":"56","author":"Jorgensen","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pedneo.2021.11.010_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pedneo.2021.11.010_bib14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib15","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1093\/cid\/ciaa1354","article-title":"Vancomycin advanced therapeutic drug monitoring: exercise in futility or virtuous endeavor to improve drug efficacy and safety?","volume":"72","author":"Dilworth","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pedneo.2021.11.010_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/antibiotics10040347","article-title":"Target attainment and clinical efficacy for vancomycin in neonates: systematic review","volume":"10","author":"Mej\u00edas-Trueba","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.pedneo.2021.11.010_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pedneo.2021.11.010_bib18","first-page":"312","article-title":"Vancomycin treatment failure in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"24","author":"Regen","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.pedneo.2021.11.010_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/17425255.2019.1655540","article-title":"Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle","volume":"15","author":"Allegaert","year":"2019","journal-title":"Expet Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pedneo.2021.11.010_bib20","series-title":"Chinese national formulary: chemicals and biological products for children","first-page":"408","author":"Jin","year":"2013"},{"key":"10.1016\/j.pedneo.2021.11.010_bib21","first-page":"2110","article-title":"Precision and accuracy of commercial assays for vancomycin therapeutic drug monitoring: evaluation based on external quality assessment scheme","volume":"75","author":"Chen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pedneo.2021.11.010_bib22","first-page":"1434","article-title":"Population pharmacokinetics of vancomycin in Chinese neonates","volume":"52","author":"Li","year":"2017","journal-title":"Chin Pharm J"},{"key":"10.1016\/j.pedneo.2021.11.010_bib23","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/jac\/dkaa320","article-title":"Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure","volume":"75","author":"Shingde","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pedneo.2021.11.010_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.pedneo.2021.11.010_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/jp.2012.36","article-title":"Distinguishing true coagulase-negative Staphylococcus infections from contaminants in the neonatal intensive care unit","volume":"33","author":"Healy","year":"2013","journal-title":"J Perinatol"},{"key":"10.1016\/j.pedneo.2021.11.010_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/17512433.2015.1060124","article-title":"How to use vancomycin optimally in neonates: remaining questions","volume":"8","author":"Jacqz-Aigrain","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.pedneo.2021.11.010_bib27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12887-016-0753-0","article-title":"Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?","volume":"16","author":"Padari","year":"2016","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.pedneo.2021.11.010_bib28","doi-asserted-by":"crossref","first-page":"106300","DOI":"10.1016\/j.ijantimicag.2021.106300","article-title":"Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing","volume":"57","author":"Tang","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pedneo.2021.11.010_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/healthcare7010028","article-title":"Rational use of antibiotics in neonates: still in search of tailored tools","volume":"7","author":"van den Anker","year":"2019","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.pedneo.2021.11.010_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00431-019-03339-2","article-title":"Neurodevelopmental outcome at 2 years of age in preterm infants with late-onset sepsis","volume":"178","author":"Zonnenberg","year":"2019","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.pedneo.2021.11.010_bib31","series-title":"Proceedings from the 54th Intersci Conf Antimicrob Agents Chemother","article-title":"Successful growth of staphylococcus epidermidis in the neutropenic mouse thigh infection model (NMTIM) without the use of a foreign body","author":"Leiva","year":"2014"},{"key":"10.1016\/j.pedneo.2021.11.010_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pedneo.2021.11.010_bib33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pedneo.2021.11.010_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146224","article-title":"Association between the AUC0-24\/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis","volume":"11","author":"Men","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pedneo.2021.11.010_bib35","first-page":"1017","article-title":"Population-based pharmacokinetic modeling of vancomycin in children with renal insufficiency","volume":"2","author":"Le","year":"2014","journal-title":"J Pharmacol Clin Toxicol"},{"key":"10.1016\/j.pedneo.2021.11.010_bib36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium","volume":"76","author":"Kufel","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pedneo.2021.11.010_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2019.02.029","article-title":"Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting","volume":"25","author":"Broeker","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pedneo.2021.11.010_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","article-title":"The dosing and monitoring of vancomycin: what is the best way forward?","volume":"53","author":"Drennan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pedneo.2021.11.010_bib39","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2146\/ajhp180034","article-title":"Making the change to area under the curve-based vancomycin dosing","volume":"75","author":"Heil","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pedneo.2021.11.010_bib40","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jpids\/piaa078","article-title":"A moving target-vancomycin therapeutic monitoring","volume":"9","author":"Burns","year":"2020","journal-title":"J Pediatr Infect Dis Soc"}],"container-title":["Pediatrics & Neonatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957222000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957222000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:55:54Z","timestamp":1761749754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875957222000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1875957222000110"],"URL":"https:\/\/doi.org\/10.1016\/j.pedneo.2021.11.010","relation":{},"ISSN":["1875-9572"],"issn-type":[{"value":"1875-9572","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records","name":"articletitle","label":"Article Title"},{"value":"Pediatrics & Neonatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pedneo.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Taiwan Pediatric Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}